Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Amimestrocel (hUC-MSC PLEB001) is a human umbilical cord-derived mesenchymal stem cell (hUC-MSC) therapy developed by Platinum Excellence Biotechnology (Beijing) Co., Ltd. It is the first mesenchymal stem cell product approved by the Chinese National Medical Products Administration (NMPA), receiving approval in January 2025. The therapy is indicated for the treatment of steroid-refractory acute graft-versus-host disease (SR-aGVHD), particularly cases with gastrointestinal involvement (SR-GI-aGVHD), following allogeneic hematopoietic stem cell transplantation. Mesenchymal stem cells exert therapeutic effects through immunomodulation, reducing inflammation, and promoting tissue repair in the affected organs.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on amimestrocel.